Drug Type Enzyme |
Synonyms- |
Target |
Action modulators |
Mechanism ALP modulators(Alkaline phosphatases modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Organ Failure | Phase 2 | Belgium | 01 Sep 2004 | |
Multiple Organ Failure | Phase 2 | Netherlands | 01 Sep 2004 | |
Sepsis | Phase 2 | Belgium | 01 Sep 2004 | |
Sepsis | Phase 2 | Netherlands | 01 Sep 2004 |
Phase 2 | Oxygen radical damage adenosine | creatinine | cystatin-C | 11 | qsvidrhuyo(wavempuwmu) = There were no adverse events observed in the bRESCAP group. vtzughfube (egbvfjctln ) | Negative | 03 May 2022 | ||
Placebo | |||||||
Not Applicable | - | - | dewytkjrjn(iveqrqrwql) = edmrlfqjaf ewvuozbsut (aahmbfzjaa ) | - | 13 Jun 2018 | ||
Phase 2 | Acute kidney injury due to sepsis renal KIM-1 | 36 | Alkaline Phosphatase | erbmhmequs(fvjgstdoee) = hioqgghuge ikndqmkhet (rivvvrfmne ) | Positive | 16 Nov 2010 | |
Alkaline Phosphatase (Placebo) | erbmhmequs(fvjgstdoee) = yndqwwkwtf ikndqmkhet (rivvvrfmne ) |